Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.
Stanford researchers have applied large-scale proteomic platforms to identify biomarkers that can be used to diagnose uveal melanoma and subtype eye tumors according to their gene expression profile (GEP) class or PRAME status.
Stanford researchers have discovered that dietary metabolites, specifically alpha-ketoglutarate, are able to delay retinal degeneration to treat blinding retinal diseases regardless of the type of retinal condition.